Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$417M Buy
1,936,859
+13,302
+0.7% +$2.54M 0.15% 175
2026
Q1
$346M Buy
1,923,557
+394,941
+26% +$72.8M 0.16% 159
2025
Q4
$269M Sell
1,528,616
-254,965
-14% -$41.7M 0.14% 183
2025
Q3
$249M Buy
1,783,581
+418,776
+31% +$56.6M 0.16% 163
2025
Q2
$171M Sell
1,364,805
-4,037
-0.3% -$503K 0.14% 194
2025
Q1
$187M Buy
1,368,842
+829,150
+154% +$119M 0.19% 124
2024
Q4
$81.9M Buy
539,692
+489,811
+982% +$82.6M 0.11% 253
2024
Q3
$9.62M Buy
49,881
+26,324
+112% +$5.51M 0.01% 817
2024
Q2
$5.46M Buy
23,557
+17,195
+270% +$3.74M 0.01% 984
2024
Q1
$1.37M Sell
6,362
-30,778
-83% -$7.21M ﹤0.01% 1563
2023
Q4
$9.61M Sell
37,140
-269,539
-88% -$66.2M 0.02% 724
2023
Q3
$78.8M Sell
306,679
-29,709
-9% -$7.95M 0.16% 160
2023
Q2
$95.7M Sell
336,388
-86,098
-20% -$25.6M 0.2% 112
2023
Q1
$117M Buy
422,486
+224,668
+114% +$62.2M 0.26% 87
2022
Q4
$54.4M Sell
197,818
-56,640
-22% -$16M 0.12% 205
2022
Q3
$65.8M Sell
254,458
-258,748
-50% -$55M 0.16% 150
2022
Q2
$103M Buy
513,206
+116,900
+29% +$23.9M 0.23% 97
2022
Q1
$83.5M Buy
396,306
+68,085
+21% +$14.8M 0.16% 145
2021
Q4
$78.7M Sell
328,221
-22,639
-6% -$5.82M 0.14% 171
2021
Q3
$99.3M Sell
350,860
-163,602
-32% -$53.6M 0.18% 131
2021
Q2
$178M Sell
514,462
-510,943
-50% -$155M 0.31% 68
2021
Q1
$284M Buy
1,025,405
+7,983
+0.8% +$2.15M 0.46% 38
2020
Q4
$245M Sell
1,017,422
-1,199,563
-54% -$309M 0.44% 43
2020
Q3
$628M Sell
2,216,985
-19,186
-0.9% -$5.35M 1.06% 11
2020
Q2
$583M Buy
2,236,171
+116,044
+5% +$34.9M 0.94% 10
2020
Q1
$661M Sell
2,120,127
-516,832
-20% -$157M 1.11% 11
2019
Q4
$781M Sell
2,636,959
-879,652
-25% -$244M 0.89% 11
2019
Q3
$815M Sell
3,516,611
-277,141
-7% -$64.5M 0.96% 8
2019
Q2
$887M Sell
3,793,752
-426,104
-10% -$98.4M 0.99% 11
2019
Q1
$992M Buy
4,219,856
+1,063,775
+34% +$335M 1.05% 8
2018
Q4
$950M Buy
3,156,081
+132,044
+4% +$42.1M 1.1% 5
2018
Q3
$1.07B Buy
3,024,037
+183,542
+6% +$63.2M 1.02% 10
2018
Q2
$824M Buy
2,840,495
+396,445
+16% +$111M 0.83% 14
2018
Q1
$669M Buy
2,444,050
+477,916
+24% +$148M 0.72% 23
2017
Q4
$626M Buy
1,966,134
+96,473
+5% +$30.9M 0.66% 27
2017
Q3
$585M Buy
1,869,661
+565,002
+43% +$167M 0.7% 21
2017
Q2
$354M Buy
1,304,659
+264,040
+25% +$69.8M 0.47% 41
2017
Q1
$285M Buy
1,040,619
+368,587
+55% +$104M 0.38% 58
2016
Q4
$191M Sell
672,032
-50,572
-7% -$15M 0.26% 88
2016
Q3
$226M Buy
722,604
+377,752
+110% +$112M 0.35% 62
2016
Q2
$83.4M Buy
344,852
+57,156
+20% +$15.1M 0.15% 197
2016
Q1
$74.9M Sell
287,696
-525,397
-65% -$139M 0.13% 214
2015
Q4
$249M Sell
813,093
-167,066
-17% -$48M 0.44% 39
2015
Q3
$286M Sell
980,159
-16,285
-2% -$5.38M 0.57% 32
2015
Q2
$403M Buy
996,444
+162,199
+19% +$65.1M 0.8% 12
2015
Q1
$352M Sell
834,245
-367,044
-31% -$145M 0.81% 10
2014
Q4
$408M Buy
1,201,289
+93,290
+8% +$30.2M 0.85% 7
2014
Q3
$367M Buy
1,107,999
+316,275
+40% +$104M 1.01% 3
2014
Q2
$250M Buy
791,724
+64,600
+9% +$19.4M 0.67% 12
2014
Q1
$222M Buy
727,124
+129,500
+22% +$41.1M 0.67% 13
2013
Q4
$167M Buy
597,624
+213,992
+56% +$55.3M 0.5% 30
2013
Q3
$92.4M Sell
383,632
-42,976
-10% -$9.62M 0.33% 60
2013
Q2
$91.8M Buy
+426,608
New +$91.2M 0.33% 59

Other funds holding BIIB

Cliff Asness's BIIB Position: Q2 2026 in Review

Cliff Asness increased its Biogen (BIIB) stake by 0.69% in Q2 2026, buying an estimated $2.54M and bringing the position to 1,936,859 shares worth $417M. The position accounts for 0.15% of the portfolio, ranked #175.

Cliff Asness first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.07B in Q3 2018. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Cliff Asness held 1,936,859 shares of Biogen worth $417M as of Q2 2026.
  • Cliff Asness bought 13,302 Biogen shares in Q2 2026, an estimated $2.54M.
  • Biogen made up 0.15% of Cliff Asness's portfolio in Q2 2026, its #175 holding.
  • Cliff Asness first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
  • Cliff Asness's Biogen position peaked at $1.07B in Q3 2018.
  • 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.